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Abstract
Background:  Cellular interactions elicited by Plasmodium falciparum erythrocyte membrane
protein antigen 1 (PfEMP1) are brought about by multiple DBL (Duffy binding like), CIDR (cysteine-
rich interdomain region) and C2 domain types. Elucidation of the functional and structural
characteristics of these domains is contingent on the abundant availability of recombinant protein
in a soluble form. A priori prediction of PfEMP1 domains of the 3D7 genome strain, most likely to
be expressed in the soluble form in Escherichia coli was computed and proven experimentally.
Methods: A computational analysis correlating sequence-dependent features to likelihood for
expression in soluble form was computed and predictions were validated by the colony filtration
blot method for rapid identification of soluble protein expression in E. coli.
Results: Solubility predictions for all constituent PfEMP1 domains in the decreasing order of their
probability to be expressed in a soluble form (% mean solubility) are as follows: ATS (56.7%) >
CIDR1α (46.8%) > CIDR2β (42.9%) > DBL2-4γ (31.7%) > DBL2β + C2 (30.6%) > DBL1α (24.9%)
> DBL2-7ε (23.1%) > DBL2-5δ (14.8%). The length of the domains does not correlate to their
probability for successful expression in the soluble form. Immunoblot analysis probing for soluble
protein confirmed the differential in solubility predictions.
Conclusion: The acidic terminal segment (ATS) and CIDR α/β domain types are suitable for
recombinant expression in E. coli while all DBL subtypes (α, β, γ, δ, ε) are a poor choice for
obtaining soluble protein on recombinant expression in E. coli. This study has relevance for
researchers pursuing functional and structural studies on PfEMP1 domains.
Background
The recent completion of sequencing of the genome of
Plasmodium falciparum has stimulated studies on new pro-
teins and biochemical systems that need further experi-
mental validation. This influx of potentially useful vaccine
and drug candidates against malaria has added to the
backlog of targets currently under validation. The bottle-
neck, imposed by the need to have soluble proteins for
functional studies, has been considerably narrowed by the
unpredictability associated with recombinant expression
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in host systems. Protein transition, from a naturally occur-
ring low concentration in vivo, to unnaturally higher con-
centrations in expression hosts often results in poor
solubility, aggregation and inclusion body formation [1].
The success of most, if not all functional and structural
studies, is contingent on the abundant availability of sol-
uble proteins.
Heterologous expression of malarial proteins is per-
formed primarily in Escherichia coli, although yeast and
insect cells are becoming increasingly popular, particu-
larly for proteins that are predicted to undergo post-trans-
lational processing. In general, E. coli, as an expression
host has advantages in terms of procedural simplicity,
well known E. coli genetics, availability of compatible
molecular tools, higher yields per unit biomass and
thereby low costs sustained. The fact that over expression
in E. coli is often associated with accumulation of recom-
binant protein as insoluble aggregates has not precluded
its usage as the expression system of primary choice. A
wide arsenal of innovative strategies has been employed
to increase the yield of soluble protein(s). These include
simultaneous over expression of molecular chaperones,
remedying codon bias with supplementation of rare
tRNAs, mRNA stabilisation strategies, use of strong pro-
moters with tight control of background expression in
protease defecient E. coli strains and optimization of cul-
ture media against limiting factors and products [2]. These
strategies although useful, however, cannot be harnessed
in a high throughput manner. Malarial genes exhibit an
A+T composition approaching 80% and show frequent
occurrence of long clusters of rare E. coli codons. Conse-
quently, premature translational termination, frameshift
events and mistranslational amino acid substitutions aris-
ing from codon bias further complicate recombinant
expression of malarial proteins in E. coli. Recombinant
expression of malarial genes in E. coli is thus confined to
trial and error.
In this setting, prior knowledge of genes or sequences that
either do or do not lend to soluble expression in E. coli is
thus of particular relevance. Mutagenesis studies provide
indirect evidence to the effect of sequence on solubility
and propensity of a polypeptide chain to aggregate into
inclusion bodies. Alteration in the primary sequence of a
protein by mutational replacement of non-polar amino
acid residues with charged ones such as lysine has been
shown to enhance intrinsic solubility of recombinant pro-
teins [3]. Specific mutations that alter the overall charge of
the peptide molecule without altering its overall hydro-
phobic nature or structure have been shown to influence
aggregation [4]. Additionally, sequence related factors
such as hydrophobicity, hydrophilic-hydrophobic pat-
terning, charge, high β-sheet and low β-turn propensities
have all been implicated in the aggregation of proteins
[5]. A pragmatic application that exploits the correlation
between sequence and solubility is evident in the screen-
ing of expression libraries. Fusion of mutants of the target
protein to a reporter with a selectable function e.g green
fluorescence protein allows for easy selection of soluble
mutants for functional studies [6].
To date, characterization of many of the well-studied pro-
teins has been possible, partly due to their higher solubil-
ity on recombinant expression. On the other hand, there
are many other proteins that have not been amenable for
biophysical studies because of a tendency to aggregate.
Attempts have been made to compare these two groups of
proteins on the basis of physicochemical parameters that
are determined by amino acid composition and are
hypothesized to be related to in vivo solubility. Based on
an in-depth analysis of the physiochemical parameters of
81 proteins for which experimental data was available,
protein charge and relative number of turns were the two
parameters found to correlate strongly with the formation
of inclusion bodies [7].
A strategy often employed to characterise complex pro-
teins is to study them at the level of individual domains.
This strategy has been effectively employed to study P. fal-
ciparum erythrocyte membrane protein 1 (PfEMP1). Each
PfEMP1 molecule contains 4–7 extra cellular domains
anchored to the erythrocyte surface through a transmem-
brane region and an acidic terminal segment (ATS) [8].
These domains, namely DBLα-ε (Duffy binding like
domains), CIDRα-γ (cysteine-rich interdomain region)
and C2 are implicated in binding to endothelial receptors,
uninfected erythrocytes and platelets and are thus subject
to structure – function investigations [9-11]. The latter is
largely dependent on the availability of soluble protein
expressed recombinantly.
An analysis conducted by Wilkinson and Harrison [7] was
applied to all the PfEMP1 domains of the 3D7 genome
parasite. Solubility predictions for individual domains
were calculated and comparison across domain groups
was conducted. Correlations between the domain length
(number of amino acid residues) per domain and propen-
sity for expression in soluble form were determined. Fur-
ther, solubility predictions for a limited set of PfEMP1




DNA and protein sequences corresponding to PfEMP1
from P. falciparum 3D7 genome strain were retrieved from
the database maintained by the National Center for Bio-
technology Information (PlasmoDB). PfEMP1 sequences
were aligned and each sequence was further divided man-Malaria Journal 2006, 5:52 http://www.malariajournal.com/content/5/1/52
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ually into constituent domains. The domain boundaries
were defined according to previously published criteria
[8].
Solubility predictions
A statistical model for prediction of solubility on expres-
sion in E. coli, as defined by Wilkinson and Harrison [7],
was used for this study. This model has been primed on
81 proteins for which expression results are available. Dis-
criminant analysis was used to compare these proteins
according to six composition related parameters viz. –
charge average, turn forming residue fraction, cysteine
fraction, proline fraction, hydrophilicity and total
number of amino acid residues. The relative number of
turn forming residues (asparagine, glycine, proline and
serine) and absolute charge per residue (fraction of posi-
tively and negatively charged amino acids), were found to
correlate strongly with inclusion body formation. A com-
posite parameter (CV-canonical variable) dependent on
the contribution of each of the individual amino acid was
derived and is as follows:
CV = 15.43 {(N + G + P + S)/n} - 29.56 {[(R + K) - (D +
E)/n] - 0.03}
where N, G, P, S, R, K, D, E are the absolute numbers of
asparagine, glycine, proline, serine, arginine, lysine, aspar-
tic acid and glutamic acid residues, respectively, and n is
the total number of residues in the whole sequence. A
threshold discriminate CV' = 1.71 [12] was introduced to
distinguish soluble proteins from insoluble ones. A pro-
tein is predicted to be soluble, if the difference between
CV and CV' is negative. On the contrary, a CV-CV' differ-
ence larger than zero, predicts the protein to be insoluble.
Further a probability of solubility was calculated from the
following equation:
P = 0.4934 + 0.276 (CV-CV') - 0.0392(CV-CV')2 [12]
Using the percentage probabilities to classify proteins as
soluble or insoluble, discriminant analysis successfully
classifies proteins as being soluble or insoluble with an
overall accuracy of 88% [7].
For the PfEMP1 domain dataset, the CV-CV' values, prob-
abilities for soluble expression in percentage, relative
number of turn forming residues, charge per residue and
length of protein sequence were compared. Additionally
mean solubility propensities along with the lower and
upper quartiles for each domain group were compared.
Expression constructs
Two sequences of similar length but belonging to differ-
ent domain types, namely DBL1α (PF13 0003/3D7) and
CIDR1α (PF08 0106/3D7) were PCR amplified with the
following primers:
5'-ATC GAG CTC TCA CTT ACA TAC AAA TTT CAT ACT
AAT-3' and 5'-GAT CTC GAG GTA TTT TTT CTT TTG TTT
TTA AAA TTC TT-3' for DBL1α PF13 0003, 5'-ATC GAG
CTC TGT GAA AAA GTT GAC GAC GAA GAA-3' and 5'-
GAT CTC GAG GGT GGC GTC TTT TAG TTC CTC T-3' for
CIDR1α PF08 0106.
The amplified PCR fragments were purified using a Qia-
gen Purification Kit (Qiagen, CA, USA). The fragments
were subsequently digested with compatible restriction
enzymes (New England Biolabs, MA, USA) and ligated
with Fast-Link TM DNA Ligation Kit (Epicentre Technolo-
gies, WI, USA) to double-digested and gel-purified pQE-
Tri-System His-Strep 2 vector (Qiagen, CA, USA). The
recombinant plasmids were transformed into TOPO com-
petent cells (Invitrogen, CA, USA) and positive recom-
binant clones were confirmed with PCR and restriction
enzyme digestion. All constructs were verified by DNA
sequencing in an ABI377 automated sequencer with a Big
Dye terminator v3.1 cycle sequencing kit (Appied Biosys-
tems, CA, USA). Another plasmid construct for the expres-
sion of ATS (FCR3S1.2) was generated as described earlier
[9]. SG10009 chemically competent E. coli cells (Qiagen,
CA, USA) were transformed with the histidine (His) and
glutathione S-transferase (GST) expression constructs.
Expression in E. coli
Experimental validation of solubility predictions was con-
ducted by employing a new method, namely colony filtra-
tion blot for rapid identification of soluble protein
expression in E. coli [13]. This method is based on the sep-
aration of soluble protein from inclusion bodies by a fil-
tration step at the colony level and has previously been
used to screen expression constructs from a deletion
mutagenesis library with 84% specificity for discrimina-
tion between soluble and insoluble expression products
in the Rosetta™ (DE3) pLysS E. coli strain. In short, cells
harbouring the expression construct were plated and
grown on an LB plate. After overnight growth, a 0.45 μm
Durapore filter membrane (Millipore, MA, USA) was
placed on top of the colonies. The membrane was peeled
off and placed carefully, with the colonies facing upwards,
on a LB plate containing 0.2 mM IPTG. Recombinant pro-
tein expression in the colonies "on the membrane" was
induced for 6 hours at room temperature. The filter mem-
brane was subsequently peeled off and placed on top of a
nitrocellulose filter and a Whatman paper, both soaked in
lysis buffer [20 mM Tris pH 8.00, 100 mM NaCl, 0.1 mg/
ml Lysozyme, 0.75 mg/ml DNAse I, 1/2 complete EDTA-
free protease inhibitor cocktail tablet/10 ml (Roche, Basel,
Switzerland)]. The "filter-sandwich" was incubated at
room temperature for 30 min and then freeze-thawedMalaria Journal 2006, 5:52 http://www.malariajournal.com/content/5/1/52
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thrice for 10 min at -80°C and 37°C respectively. The
nitrocellulose membrane was subsequently removed
from the sandwich and blocked with 1% BSA in TBST (20
mM Tris, pH 7.5, 500 mM NaCl, 0.05% Tween 20) for 1
hour. The membrane was washed 3 × 10 min in TBST and
incubated for another hour with a mouse monoclonal
Penta-His antibody (Qiagen, Hilden, Germany) or anti-
GST mouse monoclonal antibody (Sigma, USA) in1: 1000
dilution in TBST. After incubation with the primary anti-
body, the membrane was washed 3 × 10 min in TBST. Fol-
lowing the washes, an alkaline phosphatase-labelled anti-
mouse polyclonal secondary antibody (Dako, Denmark)
was added to the membrane at a 1:1000 dilution in TBST.
Reactive protein spots were visualised by incubation with
the enzyme substrate nitroblue tetrazolium-5-bromo-4-
chloro-3-indoyl phosphate (Sigma, USA).
Results and discussion
Recombinant expression of different PfEMP1 domains in
E. coli often presents the simplest approach for obtaining
protein for receptor ligand studies. Probability of solubil-
ity analysis of these domains according to Wilkinson and
Harrison [7], however, illustrates that the domains exhibit
considerable heterogeneity as regards to their propensity
for expression as soluble proteins. From amongst all
PfEMP1 domain types, the ATS domains stand out as the
ones most suitable for expression in E. coli. Seventy one
percent of the analysed ATS sequences are predicted to
exhibit expression in soluble form (Figures 1 and 2). On
the other extreme, almost all of the DBL2-5δ sequences
are predicted to exhibit low solubility of the recombinant
protein expressed in E. coli. Out of the 57 ATS domains
analysed, the mean solubility for this domain types is pre-
dicted to be 56.7% (range: 25.7% – 80.3%). In compari-
son, the average solubility for the DBL2-5δ domain type is
predicted to be 14.8% (range: 3.8% – 31.1%) and is
thereby unsuitable for expression in E. coli. The DBL1α
and CIDR1α domain types, which in tandem comprise
PfEMP1 "head-structure", however, exhibit different pro-
pensities for expression in a soluble form in E. coli. While
Distribution of CV-CV' values for all domains harboured on PfEMP1 molecules of the 3D7 genome parasite Figure 1
Distribution of CV-CV' values for all domains harboured on PfEMP1 molecules of the 3D7 genome parasite. 
CV-CV' values computed for all PfEMP1 domains were plotted against domain length. Negative CV-CV' values predict the 
domain to be soluble, while positive values predict the domain to be insoluble on expression in E. coli. Dashed boxes enclose all 
domains belonging to a particular domain type. ATS domains are plotted as squares (dark blue), CIDR domains as circles with 
a central dot (CIDRα – red, CIDR2β – cyan) and DBL domains as solid circles (DBL1α – grey, DBL2β + C2 – green, DBL2-4γ 
– magenta, DBL2-5δ – grey and DBL2-7ε – yellow).Malaria Journal 2006, 5:52 http://www.malariajournal.com/content/5/1/52
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a significant proportion of CIDR1α domains were pre-
dicted to result in soluble expression, the opposite was
true for the DBL1α domains. The mean solubility for
CIDR1α domains, while being only marginally lower
than that of ATS domains, is approximately twice that of
DBL1α domains (46.8% vs. 24.9%). The CIDR2β
domain, a domain that exhibits significant internal con-
servation and is closely related to the CIDR1α domain,
was predicted to exhibit 42.4% probability for expression
in soluble form in E. coli. The DBL2β + C2 domain, a tan-
dem domain implicated in intercellular adhesion mole-
cule 1 (ICAM-1) binding, was predicted to be fairly
insoluble (30.6% mean probability of solubility) on
recombinant expression in E. coli. The DBL2-4γ and
DBL2-7ε domains – domain types encountered infre-
quently on PfEMP1 molecules, were also predicted to give
low soluble expression in E. coli (mean solubility proba-
bilities of 31.6% and 23.1% respectively). Taken together
a gradient in probabilities for soluble expression for
PfEMP1 domain types was observed. All PfEMP1 domains
could thus be ordered in decreasing order of their proba-
bility for soluble expression as follows:
ATS > CIDR1α > CIDR2β > DBL2-4γ > DBL2β + C2 >
DBL1α > DBL2-7ε > DBL2-5δ
DBL domains in general are poor choices for obtaining
recombinant protein in soluble form on expression in E.
coli. On the contrary ATS and CIDR domains are fairly
good choices for obtaining soluble protein on recom-
binant expression in E. coli.
The solubility predictions computed according to the
model proposed by Wilkinson and Harrison [7] were con-
firmed experimentally in a small expression series in E.
coli. In order to detect clear differences in soluble protein
expression, three domain types viz. ATS, CIDR1α and
DBL1α with a fairly wide range of solubility probabilities
were selected for expression in E. coli. Additionally, the
latter two domain types have been implicated in various
cellular interactions and are therefore subject to regular
attempts to obtain the same in a soluble form. A fairly
simple and robust technique of colony blot filtration was
employed to document soluble protein expression. This
technique relies on the induction and subsequent lysis of
E. coli colonies on a filter membrane. The soluble proteins
Box Plot summarizing predictions for obtaining soluble protein on recombinant expression of all constituent domain types on  PfEMP1 molecules Figure 2
Box Plot summarizing predictions for obtaining soluble protein on recombinant expression of all constituent 
domain types on PfEMP1 molecules. The boxes illustrate the first and third quartiles with whiskers extending over the 
interquartile range of the first and third quartiles. A horizontal line placed across the width of the box illustrates the median. 
Outliers are indicated by asterisk (*) and means by a plus sign (+). The numerical mean solubility for each domain is indicated 
adjacent to the latter. The frequency (n) of each domain in the dataset is indicated below the respective domains.Malaria Journal 2006, 5:52 http://www.malariajournal.com/content/5/1/52
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diffuse through the filter membrane and are captured on
to a nitrocellulose membrane placed under the filter
membrane. The cellular debris and inclusion bodies are
retained on the filter membrane or subsequently removed
during the washing steps. Figure 4 clearly shows variation
in the level of recombinant expression as soluble protein
for these three PfEMP1 domain types. Detection with anti-
bodies to fusion tags shows spots indicating the presence
of soluble protein on the blots, which correspond to the
number of colonies expressing the cloned domain.
Extremely low signals from the blot harboring colonies
expressing the DBL1α PF13 0003 domain, confirms the
computational solubility assignment for this particular
domain (6.9%). On the contrary, the intensity of signals
from colonies expressing an equally long but a different
domain type (CIDR1α) is intense, indicating a higher
yield of soluble protein. A similar outcome was predicted
by computational analysis, which assigned this particular
domain a solubility probability of 79%. As predicted, the
yield of soluble protein was highest on expression of an
ATS domain, as evident from the intensity of the dots on
the colony blot.
No correlation between the length of the domain and the
probability of expression in a soluble form (Figure 1) was
observed. In fact, the largest of the domains in the dataset,
ATS and CIDR2β, with mean ± SD domain lengths of 482
± 29 and 454 ± 72 amino acid residues respectively, were
predicted to give higher soluble protein on expression in
E. coli. DBL2-7ε domains, although being smallest (254 ±
19 amino acid residues) in the whole dataset, were how-
ever predicted to be confined to insoluble states on
recombinant expression. The fates of DBL1α and CIDR1α
domains, with similar mean domain lengths of 314 ± 13
and 310 ± 38 amino acid residues respectively, were pre-
dicted to dimensionally opposite states on recombinant
expression. While CIDR1α domains were predicted to
give soluble protein on E. coli expression, the opposite
was true for DBL1α domains. Further, as Figure 4 con-
firms, DBL1α and CIDR1α domains of identical lengths
(318 amino acid residues), gave different intensity of
spots when probed for soluble protein expression in E.
coli.
An attempt was made to study the variation in predictions
for expression in soluble form over the length of each
domain type (Figure 3A and 3B). Sequences of each
domain type were sorted in the increasing order of their
lengths. Means of domain lengths of blocks of five
domains were plotted against the mean solubility predic-
tions (%) for the corresponding five domains in the block.
As expected, no unambiguous relationships between pre-
dictions for soluble expression and increase in size of the
domain could be observed. This underscores the fact that
sequence per se and not its length is the primary determi-
nant of the fate of a domain to be expressed in a soluble
or insoluble state. Avoiding stretches in domains pre-
dicted to drag the protein to insoluble states could thus be
excluded when attempting recombinant expression in E.
coli [14].
Expression of heterologous genes especially of malarial
origin in E. coli, often results in the accumulation of
highly pure recombinant protein in a totally or partially
Computational predictions (%) for soluble expression as a  function of the length of the domain Figure 3
Computational predictions (%) for soluble expression 
as a function of the length of the domain. Representa-
tives of each domain type were sorted out in the increasing 
order of their length. Means of domain lengths of blocks of 5 
domains were plotted against the mean solubility predictions 
(%) for the corresponding five domains in the block. A) DBL 
domains are indicated as follows: DBL1α (solid line), DBL2β 
+ C2 (dashed line), DBL2-4γ (dotted line), DBL2-5δ (long-
dashed line), DBL2-7ε (combined dash-dotted line). B) ATS 
domains are indicated by a dotted line, CIDRα by a solid line 
and CIDR2β domains by a dashed line.Malaria Journal 2006, 5:52 http://www.malariajournal.com/content/5/1/52
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unfolded conformation as insoluble aggregates com-
monly referred to as inclusion bodies [15]. The major
determinants of expression for many proteins are the ther-
modynamic and kinetic properties of an intermediate,
rather than by the solubility and stability of the final state.
Many turn-forming residues slow down protein folding,
resulting in a high concentration of folding intermediates
incompatible with folding rates resulting in aggregation of
the protein. Solubility has also been correlated inversely
to the hydrophobic nature of the protein [16]. The total
charge of the aggregation-prone state of a protein strongly
influences its propensity to aggregate. The propensity of
charged residues as "structural gatekeepers" against aggre-
gation does not, however, appear to be based only on the
ability of these residues to interrupt contiguous stretches
of hydrophobic residues, but also their ability to generate
electrostatic repulsions between protein molecules. The
higher the net charge, the higher the repulsion between
proteins and hence lower the probability for aggregation.
Appropriate interactions involving key residues i.e.
cysteine also ensures that a newly synthesized chain of
amino acids transforms into a correctly folded protein.
But the mechanisms by which these residues affect the sol-
ubility status of an expressed protein remain to be under-
stood.
Besides, the primary sequence of a protein, a multitude of
external parameters such as culture media composition,
growth temperature, production rate as a function of plas-
mid copy, promoter strength, codon usage and mRNA sta-
bility, all have a decisive influence on the expression of
recombinant proteins. Even if the solubility algorithms
predict a particular sequence to be confined to an insolu-
ble state, alterations in these parameters can have an over-
riding effect on the final outcome [1]. Changing
expression hosts can, however, be the preferred alternative
to the time consuming and often uncertain option of opti-
mizing physical parameters to obtain soluble protein. In
vitro refolding procedures, although specific for each pro-
tein, are another useful option to obtain native protein in
a non-high throughput setting [17].
As illustrated in the case of P. falciparum apical membrane
antigen 1, recombinant proteins derived from E. coli or
alternate expression hosts are functionally and immuno-
logically equivalent [18]. Glycosylation patterns intro-
duced on proteins expressed in non – E. coli expression
hosts often impede crystallographic studies. Substantial
evidence is beginning to surface regarding the functional-
ity and immunological equivalence of merozoite surface
protein purified and refolded from bacterial inclusion
bodies [19]. Additionally, the fact that a significant pro-
portion of vaccine candidates in the developmental pipe-
line have been expressed in E. coli provides ample proof of
the unfailing enthusiasm for recombinant expression in E.
coli.
Colony Filtration Blots for identification of soluble protein expression in E. coli Figure 4
Colony Filtration Blots for identification of soluble protein expression in E. coli. E. coli colonies expressing domains 
ATS, CIDR1α and DBL1α were induced and lysed on a membrane filter. Soluble protein from each cell within the colony dif-
fuses through the filter and is captured on a nitrocellulose membrane placed under the membrane filter [13]. Detection with 
antibody reagents directed against the fusion tag, shows spots indicating the presence of soluble protein. Intensity of the spot 
corresponds to the yield of soluble protein. The arrow shows the increasing expression of soluble protein for the PfEMP1 
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Conversion of sequence data into biological reagents,
namely proteins for experimental validation and charac-
terization pose a significant challenge. Studying the pri-
mary protein sequence can, however, lend important
inferences regarding the correlations between solubility
and successful expression. A database assembling the suc-
cesses and failures of recombinant expression of malarial
genes in E. coli can further complement the accuracy of
algorithms predicting soluble expression. Consequently,
resources and costs can be channeled appropriately to
expedite the delivery of a much-needed vaccine against P.
falciparum malaria.
Conclusion
Recombinant expression of malarial genes in E. coli is well
recognized for its unpredictability. Screening of PfEMP1
domains for solubility traits for recombinant expression
in E. coli allows prediction of the final outcome and can
be applied as a valid tool for pursuing functional and
structural studies on these domains.
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